Ranbaxy Laboratories has launched generic esomeprazol tablets used for treating ulcers in the United Kingdom.

Ranbaxy (UK) Ltd, a wholly owned subsidiary of Ranbaxy Laboratories Ltd, has launched esomeprazole tablets in strengths of 20 mg and 40 mg, in the UK, the company said in a statement today.

Esomeprazole is used in the treatment of dyspepsia, peptic ulcer disease (PUD), gastroesophageal reflux disease (GORD/GERD) and Zollinger-Ellison syndrome.

Ranbaxy’s product is the first approved generic bio-equivalent version of AstraZeneca’s ‘Nexium’ in the UK market. According to IMS June 2011 data, esomeprazol tablets had sales of £60 million in that country, the statement added.

Commenting on the development, Ranbaxy Europe Regional Director, Mr Debashis Dasgupta, said: “We are committed to bringing high quality, affordable medicines for the benefit of patients and healthcare systems worldwide and in Europe. The introduction of esomeprazole in the UK is an important and significant step in this direction.”

The company would offer the product through pharmacies, retail and wholesale stores with immediate effect.

Meawhile, the sShares of Ranbaxy Laboratories were trading at Rs 473.30 on the Bombay Stock Exchange in the afternoon trade, down 1.07 per cent from its previous close in line will an overall downward trend in the market.

Related Topics